Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations
The justices rejected drugmakers’ appeals, leaving negotiated prices in place after Medicare saved several billion dollars in the first rounds, CMS said.
- The Supreme Court rejected high-profile appeals from major pharmaceutical companies on Monday, allowing the federal government to continue directly negotiating Medicare prescription drug prices.
- By declining to review the challenges, the justices left intact a lower appellate court ruling that dismissed the industry's claims that the mandatory negotiation process violates their constitutional rights.
- Drug manufacturers had fiercely argued that the program's steep tax penalties for non-compliance essentially amounted to an unconstitutional "taking" of private property and compelled speech.
- Despite receiving zero Republican votes during its 2022 passage under the Biden administration, the cost-cutting program has been fully embraced and defended in court by the Trump administration.
46 Articles
46 Articles
Supreme Court deals blow to Big Pharma
Presented by Coalition to Strengthen America’s Healthcare {beacon} View Online Health Care Health Care PRESENTED BY The Big Story Supreme Court deals blow to pharma challenge of Medicare price negotiation The Supreme Court declined to take up petitions from several of the country’s largest pharmaceutical companies challenging the Medicare drug price negotiation program. © Jacquelyn Martin, Associated...
Supreme Court Rejects Pharma Challenge to Medicare Price Negotiations
The Supreme Court on May 18 declined to consider appeals by six pharmaceutical companies challenging the government’s ability to negotiate prescription drug prices for the Medicare program. The decision effectively ends those lawsuits, all but guaranteeing that the Medicare Prescription Drug Price Negotiation Program, authorized by Congress in 2022, will continue. “The Supreme Court did not find the issues presented very interesting, instead est…
Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations with government
The negotiation program was created as part of the 2022 Inflation Reduction Act, which capped years of debate over whether the federal government should be allowed to haggle directly with manufacturers over the prices of drugs in Medicare.
On Monday, the U.S. Supreme Court rejected a series of appeals from several of the country's largest pharmaceutical companies challenging a program that forces companies to negotiate with Medicare the prices of some of their drug companies.
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
